Nuvation Bio is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies for patients with advanced cancers. The company leverages an integrated drug discovery platform to identify and optimize small molecule and biologic candidates across a range of hematological malignancies and solid tumors. Nuvation Bio’s scientific team employs structure-based design, translational research and patient-centric clinical trial strategies to accelerate the path from target validation to regulatory submission.
The company’s pipeline comprises multiple programs in Phase 1 and Phase 2 studies, each designed to address cancers with high unmet medical need. Nuvation Bio advances both single-agent and combination approaches, collaborating with academic institutions and contract research organizations to evaluate safety, pharmacokinetics and preliminary efficacy. Its lead programs target kinase inhibitors, immuno-oncology pathways and novel mechanisms of action that may overcome resistance observed with existing therapies.
Founded in 2016 under the name Nuvation Pharmaceuticals and rebranded as Nuvation Bio in 2022, the company has assembled a leadership team with deep expertise in oncology drug development, regulatory affairs and commercial strategy. This team has guided Nuvation Bio through strategic financing rounds, an initial public offering on the New York Stock Exchange and the establishment of global research partnerships, positioning the company for sustained growth.
Headquartered in Princeton, New Jersey, Nuvation Bio operates research and development facilities across North America and Europe. The company’s multidisciplinary workforce collaborates closely with patient advocacy groups, clinicians and regulatory authorities to design trials that reflect real-world patient populations. Nuvation Bio remains committed to advancing transformative therapies that improve outcomes for cancer patients worldwide.
AI Generated. May Contain Errors.
